Galux vs Latent Labs (2026)

AI Health Index verifiedOctober 9, 2026
Verdict

Both design antibodies and proteins from scratch and post technical preprints on the work, and they reach a buyer differently. Galux pairs AI with the physics of protein folding, designing from first principles, and works through pharmaceutical partnerships, with AstraZeneca and with Dong-A ST on antibodies for antibody drug conjugates. Latent Labs runs its models as a product: a browser platform and an API with a free daily quota for approved researchers and paid credits for larger campaigns, plus an agent that runs a full design campaign, with technical reports across several molecule types. Galux is the one for a team drawn to a physics informed design engine and a partnership model, with antibody drug conjugate work in view. Latent is the one for a team that wants to run de novo design itself, starting on a free tier.

The case for Galux
  • A design engine combining AI with atomistic physics, aimed at proteins and antibodies from first principles.
  • A partnership model, with AstraZeneca and a Dong-A ST collaboration on antibody drug conjugate antibodies.
  • A fit for teams interested in a physics informed approach delivered through collaboration.
The case for Latent Labs
  • A self serve platform and API with a free daily quota and paid credits.
  • Technical reports across antibodies, nanobodies and macrocyclic peptides, with a ten donor immunogenicity panel.
  • An agent that runs a whole design campaign from a written goal.

This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Galux and Latent Labs are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded

At a Glance

Plain facts

Fact Galux Latent Labs
Primary category Drug Discovery AI Drug Discovery AI
Headquarters Seoul, Republic of Korea London, United Kingdom
Website galux.co.kr latentlabs.com
Attribute Matrix

Side by Side

Axis
G
Galux
L
Latent Labs
AI Centrality
Autonomy and Oversight Model
Model and Technology Transparency
Model Supply Chain Disclosure
Clinical and Operational Evidence
AI Safety and PHI Stewardship
HIPAA and BAA Posture
Security Certifications and Trust Center
FDA and Regulatory Status
AI Governance and Bias Disclosure
AI Liability and Recourse
EHR and Interoperability Depth
Deployment Model and Data Residency
Commercial Transparency
Setting and Specialty Coverage
Citable Summaries

Each record in one paragraph

Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.

Galux

The AI Health Index awards Galux its top capability grade on AI Centrality. Set against Latent Labs, Galux does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Clinical and Operational Evidence and Security Certifications and Trust Center. Its thinnest published disclosure sits on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, October 2026

Latent Labs

The AI Health Index awards Latent Labs its top capability grade on AI Centrality. Set against Galux, Latent Labs grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Its thinnest published disclosure sits on Security Certifications and Trust Center and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.

Source: AI Health Index, October 2026

FAQ

Questions buyers ask

Should we choose Galux or Latent Labs?

The AI Health Index grades Latent Labs higher than Galux on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Galux does not grade higher on any scored axis.

Where do Galux and Latent Labs differ most?

The widest separation the AI Health Index records between Galux and Latent Labs is on AI Safety and PHI Stewardship, where Galux grades D and Latent Labs grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.

Where do Galux and Latent Labs grade the same?

The AI Health Index grades Galux and Latent Labs the same on several axes, including AI Centrality, Clinical and Operational Evidence and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.

What have Galux and Latent Labs not disclosed?

At the last review, at least one of Galux and Latent Labs published thin or absent detail on several axes, including AI Safety and PHI Stewardship, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.

Keep Comparing

Related comparisons

Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.

Disclosure

Both records were reviewed in October 2026. Galux works through partnerships and publishes no price; Latent offers a free tier with paid credits and partnerships. Both post preprints or technical reports rather than peer reviewed papers.

Ask both for design success rates with denominators on targets like yours, and how each reports the designs that failed in the lab.